Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

Resmetirom in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis
Jamal, Fares , Elshaer, Amani , Odeh, Nour B., Alatout, Mayar H., Shahin, Tala, Worden, Astin R., Albunni, Hashem , Jayasekera, Channa R. , Chascsa, David M. , Vargas, Hugo E. , Aqel, Bashar , Albunni, Hashem N , Lizaola-Mayo, Blanca C, Jayasekera, Channa R , Chascsa, David M H, Aqel, Bashar A. , Vargas, Hugo E , Jamal, Fares , Lizaola‐Mayo, Blanca

Life | August 18, 2025 | Volume: 15 | Issue: 8 | Pages: 1306

10.3390/life15081306 | PMID 40868953 Get It

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are among the most prevalent causes of chronic liver disease worldwide, closely linked to the global rise in overweight and obesity, type 2 diabetes, and metabolic syndrome. Until recently, treatment options were limited to lifestyle interventions, with no approved pharmacologic therapies. Resmetirom, a liver-directed, selective thyroid hormone receptor beta (THR-β) agonist, is a promising disease-modifying agent that targets hepatic lipid metabolism, inflammation, and fibrosis. Clinical trials, including the pivotal phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials, have demonstrated significant improvements in liver fat reduction, lipid profiles, histological endpoints, and health-related quality of life, with a favorable safety profile. In March 2024, the FDA granted accelerated approval of resmetirom for adults with MASH and moderate-to-advanced fibrosis, marking a significant milestone in MASLD treatment. This review discusses the mechanistic rationale, preclinical data, and pivotal clinical trial outcomes supporting resmetirom’s role in MASLD/MASH management, while outlining ongoing research needs, including long-term safety, pediatric evaluation, and biomarker development for optimized patient selection.
Reversing cardiac hypertrophy and heart failure using a cardiac targeting peptide linked to miRNA106a
Lü, Ming , Cai, Siqi , Korolowicz, Kyle , Deng, Claire, Taskintuna, Kaan, Yurko, Ray, Islam, Kazi , Schoonover, Bryn, Lopuszynski, Jack , Wang, Hongkun , Gallicano, G. Ian , Lopuszynski, Jack B, Gallicano, G Ian , Cai, Siqi, Ahern, Gerard P. , Zahid, Maliha

Clinical and Translational Medicine | August 18, 2025 | Volume: 15 | Issue: 8 | Pages: No page available

10.1002/ctm2.70432 | PMID 40820483 Get It

Abstract Background One in five adults aged 40 will develop heart failure (HF) during their lifetime. Risk factors (e.g., hypertension, diabetes mellitus, coronary artery disease, etc.) lead to structural and functional changes in cardiomyocytes, resulting in HF. At the cellular level, these changes consist of mis/over‐expression of genes that regulate cardiac identity (e.g., CamK2δ, PKC, Stat3, etc.). The current paradigm for treating HF is pharmacological or device‐based intervention; however, with few exceptions, the condition worsens with time. We are proposing to implement a change in HF treatment, shifting from a drug‐centric system to a cardiac target‐specific molecular approach that would reverse hypertrophy and adverse remodelling of affected cardiomyocytes. Methods A cardiomyocyte targeting peptide (CTP) was reversibly linked to miRNA106a for delivery to a mouse model of HF. Reversal of morphological, signalling, and physiological HF parameters was measured. Additionally, CTP‐miRNA106a was introduced into a human cardiomyocyte cell line to identify mechanism(s) at play for reversing HF characteristics (e.g., hypertrophy). Results Bio‐distribution studies showed that intravenously injected CTP‐miRNA106 delivered its cargo specifically to the heart within 30 min, followed by clearance of CTP from the heart to the kidneys, and to a lesser extent, the liver by 35 h with persistence of miRNA106a in cardiomyocytes until day 7 (the latest tested time‐point). CTP‐miRNA106a reversed angiotensin2/isoproterenol‐induced hypertrophy in 90% of the treated mice. We also identified two potential HF intracellular signalling pathways/mechanisms (PLCβ1/PKC/IP3 and NF‐κB) targeted by CTP‐miRNA106a that could benefit many pathophysiologies underlying HF, including inflammation. Conclusions CTP‐miRNA106a, a first‐of‐a‐kind cardiac‐specific drug, downregulates genes involved in cardiac hypertrophy and inflammation through the PLCβ1 and CamKIIδ kinase pathways. CTP delivery of miRNA106a cargo is specific to cardiomyocytes both in vitro and in vivo, and once delivered, many HF parameters, including hypertrophy, are reversed. Key points Cardiac Targeting Peptide (CTP) delivers, specifically to the heart, reversibly linked miRNA106a. MiRNA106a targets genes in various pathways known to cause heart failure when they are over/hyper activated returning their expression to normal levels. In vivo analyses using a mouse heart failure model resulted in reversal of heart failure parameters in 19/20 mice.
Diagnostic Utility of PRAME in Rare Melanoma Mimics: A Comparative Analysis Including GNET, MMNST, Epithelioid MPNST, and MITF‐Rearranged Melanocytic Tumors
Shah, Ahmed , Molligan, Jeremy , Dehner, Carina , Torres‐Mora, Jorge , Shah, Ahmed , Molligan, Jeremy F , Dehner, Carina A , Shah, Ahmed

Journal of Cutaneous Pathology | August 18, 2025 | Volume: 52 | Issue: 11 | Pages: 710-719

10.1111/cup.14849 | PMID 40819908 Get It

ABSTRACTBackgroundDifferentiating metastatic melanoma from histologic mimics such as malignant gastrointestinal neuroectodermal tumor (GNET), malignant melanotic nerve sheath tumor (MMNST), and epithelioid malignant peripheral nerve sheath tumor (EMPNST) poses significant diagnostic challenges due to overlapping morphology and immunophenotypes. PRAME is a novel immunohistochemical marker increasingly used to distinguish melanoma from its mimics, but remains underexplored in these rare tumor types.MethodsPRAME immunohistochemistry was performed on four GNETs, seven MMNSTs, 10 EMPNSTs, 16 metastatic melanomas (including eight undifferentiated melanomas), and two MITF‐rearranged melanocytic tumors. PRAME expression was scored from 0 to 4+ based on the percentage of tumor nuclei showing moderate to strong staining.ResultsAll GNETs, MMNSTs, and MITF‐rearranged tumors were PRAME‐negative. EMPNSTs showed variable expression: six were negative (0–1), one equivocal (2+), and three positive (3–4+). Fifteen of 16 melanomas were PRAME‐positive. PRAME scores differed significantly among tumor types (p = 1.99 × 10−5). PRAME demonstrated high sensitivity and specificity for distinguishing metastatic melanoma from primary mimickers including GNET and MMNST, but low specificity in EMPNST (71.4%).ConclusionsPRAME reliably distinguishes metastatic melanoma from GNET and MMNST, supporting its use in this differential. However, its reduced specificity in EMPNST limits its standalone diagnostic value in this context, emphasizing the need for a multimodal approach.
Recognition and Management of Iatrogenically Induced Opioid Dependence and Withdrawal in Children: Clinical Report
Siegel, Linda, Wilder, Robert T. , Good, Julie , Reigart, J. Routt, Eckstein, Olive S. , Hindman, Diane E., Verhoef, Philip A. , Watt, Kevin , Care, Section on Critical, Hsu, Benson, Huh, Jimmy W. , Lowrie, Lia, Ndely, Simon-Noel, Satchell, Margaret A., Medicine, Section on Anesthesiology and Pain, Chatterjee, Debnath , Diaz, Christina, Drum, Elizabeth T. , Sun, Lena S. , Willer, Brittany L. , Landrigan‐Ossar, Mary, Adler, Adam C. , Goldman, Jennifer L. , Hindman, Diane E., Care, Section on Critical, Ndely, Simon-Noel, Srinivasan, Vijay , Medicine, Section on Anesthesiology and Pain, Long, Justin B.

Pediatrics | August 18, 2025 | Volume: 156 | Issue: 3 | Pages: No page available

10.1542/peds.2025-073169 | PMID 40819838 Get It

Opioids are often prescribed to children for pain relief related to procedures, acute injuries, and chronic conditions. Around-the-clock dosing of opioids can produce physiologic opioid dependence within 5 days. According to a 2001 consensus paper from the American Academy of Pain Medicine, American Pain Society, and American Society of Addiction Medicine, dependence is defined as “a state of adaptation that is manifested by a drug class specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, or administration of an antagonist.” The experience of children undergoing iatrogenic withdrawal symptoms is variable and may be mild and go unreported or can be severe and even life threatening. Guidance on opioid withdrawal is available only for adults and primarily for adults with substance use disorders. This report will summarize existing literature and provide readers with information on how to screen for symptoms of iatrogenic opioid withdrawal as well as mechanisms for opioid withdrawal prevention.
Lifecycles of Cochrane Systematic Reviews (2003–2024): A Bibliographic Study
Li, Shiyin , Wu, Chong, Zhang, Zichen , Xiao, Mengli , Murad, M. Hassan , Lin, Lifeng , Murad, M Hassan , Lin, Lifeng

Cochrane Evidence Synthesis and Methods | August 17, 2025 | Volume: 3 | Issue: 5 | Pages: No page available

10.1002/cesm.70043 | PMID 40838186 Get It

ABSTRACT Background and Objectives The relevance of Cochrane systematic reviews depends on timely completion and updates. This study aimed to empirically assess the lifecycles of Cochrane reviews published from 2003 to 2024, including transitions from protocol to review, update patterns, and withdrawals. Methods We extracted data from Cochrane Library publications between 2003 and 2024. Each review topic was identified using a unique six‐digit DOI‐based ID. We recorded protocol publication, review publication, updates, and withdrawals (i.e., removed from the Cochrane Library for editorial or procedural reasons), calculating time intervals between stages and conducting subgroup analyses by review type. Results Of 8137 protocols, 71.9% progressed to reviews (median 25.7 months), 2.4% were updated during the protocol stage, and 10.0% were withdrawn. Among 8477 reviews, 64.3% were never updated by the time of our analysis; for those updated at least once, the median interval between updates was 57.2 months. Withdrawal occurred in 2.5% of reviews (median 67.6 months post‐publication). Subgroup analyses showed variation across review types; diagnostic and qualitative reviews tended to have longer protocol‐to‐review times than other types of reviews. Conclusions Cochrane reviews show long development and update intervals, with variation by review type. Greater use of automation and targeted support may improve review efficiency and timeliness.
6-Minute Walk Test reference equation for individuals with Class III obesity in the U.S.: a comparison with an Italian cohort
Abdurakhimova, Dilbar , Choi, Sunghwan , Macheel, Joy M. , Bednarchuk, Heidi C. , Lım, Wootaek , Choi, Sunghwan

Disability and Rehabilitation | August 17, 2025 | Volume: 48 | Issue: 3 | Pages: 779-787

10.1080/09638288.2025.2545594 | PMID 40819293 Get It

Trends and Disparities in Ventricular Tachycardia-Related Mortality According to Cardiomyopathy Type in the United States
Estrada-Magana, Andres , Siontis, Konstantinos C. , Liang, Jackson J. , Liang, Jackson , Sheffeh, Mohammad Ali , Lavallaz, Jeanne du Fay de

No container title available | August 17, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.175543396.66391526/v1 Get It

HFpEF-ABA score is a more useful enrichment tool than natriuretic peptides in heart failure with preserved ejection fraction
Borlaug, Barry A. , Ou, Yang , Hurt, Karla, Murakami, Masahiro, Packer, Milton , Packer, Milton , Borlaug, Barry A , Murakami, Masahiro , Zile, Michael R. , Kramer, Christopher M. , Litwin, Sheldon E. , Ye, Wenyu

European Heart Journal | August 16, 2025 | Volume: 46 | Issue: 43 | Pages: 4607-4609

10.1093/eurheartj/ehaf663 | PMID 40886160 Get It

Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?
Jang, Albert , Tripathi, Nikita , Lanka, Sree M , Calaway, Adam , Shoag, Jonathan E. , Vince, Randy , Mendiratta, Prateek, Rao, Santosh, García, Jorge A. , Koshkin, Vadim S. , Barata, Pedro C. , Calaway, Adam , Vince, Randy , Brown, Jason R , Koshkin, Vadim S , Barata, Pedro , Jang, Albert , Kumar, Hamsa L.S. , Jain, Prateek, Brown, Jason R. , Campbell, Matthew T. , Singh, Parminder

The Oncologist | August 16, 2025 | Volume: 30 | Issue: 9 | Pages: No page available

10.1093/oncolo/oyaf259 | PMID 40828887 Get It

Abstract The combination of enfortumab vedotin and pembrolizumab (EVP) has recently revolutionized care for patients with previously untreated locally advanced and metastatic urothelial carcinoma. However, predictive biomarkers of response, the optimal duration of EVP for patients who respond well to therapy, and the role of circulating tumor DNA to monitor treatment response have not yet been fully elucidated. In this molecular tumor board, we summarize 6 patients from 4 different academic institutions with unresectable or oligometastatic urothelial carcinoma who achieved long-term remission on surveillance after a short duration of EVP treatment that resulted in complete response on follow-up imaging followed by consolidative radical cystectomy. We discuss potential predictive biomarkers for patients with exceptional response to EVP. These findings highlight the need to determine an optimal duration of EVP to maximize efficacy while minimizing adverse events. We aim to further define and explore the value of local therapy with consolidative cystectomy in the setting of unresectable, locally advanced, oligometastatic disease, or those with metastatic disease who achieve complete response of disease outside of the bladder. Identifying this subset of patients who may be candidates for this type of multidisciplinary management may result in durable treatment-free remission.
Unveiling Misdiagnosis: Rethinking Seronegative NMOSD
Lang, Mary V. , Welk, Grant M., Tajfirouz, Deena , Chodnicki, Kevin D. , Pittock, Sean J., Chen, John J. , Tajfirouz, Deena , Flanagan, E P , Chen, John J , Welk, Grant M. , Lang, Mary , Pittock, Sean J., Flanagan, Eoin P.

Multiple Sclerosis Journal | August 16, 2025 | Volume: 31 | Issue: 11 | Pages: 1381-1384

10.1177/13524585251360648 | PMID 40817768 Get It

Seronegative neuromyelitis optica spectrum disorder (NMOSD) is a diagnostic challenge. This study aimed to characterize misapplication of the 2015 international criteria for seronegative NMOSD. We reviewed 35 consecutive seronegative NMOSD referrals to a tertiary center. Two (6%) met formal criteria, and 2 (6%) were clinically suspected of NMOSD without fulfilling radiologic supportive criteria. Alternative diagnoses were common including multiple sclerosis (37%), optic neuritis (14%), functional neurologic disorder (11%), and other (38%). Immunosuppression with rituximab was used in 3 of 4 patients with functional neurologic disorder. Misapplication of the 2015 criteria is common, and alternative explanations in seronegative NMOSD patients should be strongly considered.